期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

单倍体造血干细胞移植后高剂量环磷酰胺诱导免疫耐受治疗再生障碍性贫血的研究 被引量：3

原文传递
导出
摘要 异基因造血干细胞移植（allo-HSCT）是根治重型再生障碍性贫血（SAA）的有效手段,而单倍体造血干细胞移植具有中国特色的移植体系,在国际上处于领先水平.但单倍体造血干细胞移植后致死性的感染及移植物抗宿主病（GVHD）是影响移植预后的主要因素.近来临床治疗中发现,诱导免疫耐受新方法即移植后高剂量环磷酰胺（CTX）应用于SAA的治疗,降低了GVHD和移植相关病死率.本文就单倍体造血干细胞移植后,应用高剂量CTX诱导免疫耐受的形成治疗SAA的相关性研究做如下综述.
作者 郭智 陈惠仁
机构地区 北京军区总医院血液科
出处 《中华器官移植杂志》 CAS CSCD 2015年第12期753-755,共3页 Chinese Journal of Organ Transplantation
基金 基金项目：国家自然科学基金（31200686） 北京市首都临床特色课题（Z151100004015218）
关键词 异基因造血干细胞移植 重型再生障碍性贫血 免疫耐受治疗 环磷酰胺 移植后 单倍体 高剂量 酰胺诱导
分类号 R556.5 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献26

  • 1郭智,陈惠仁,刘晓东,杨凯,楼金星,何学鹏,张媛,陈鹏.单倍型异基因造血干细胞移植治疗儿童重型再生障碍性贫血[J].中华实用儿科临床杂志,2014,29(15):1145-1148. 被引量：23
  • 2Szpecht D, Gorczynska E, Ka? wak K, et al. Matched siblingversus matched unrelated allogeneic hematopoietic stem celltransplantation in children with severe acquired aplasticanemia: experience of the polish pediatric group forhematopoietic stem cell transplantation [J]. Arch ImmunolTher Exp (Warsz), 2012, 60(3):225-233.
  • 3Kim H,Kim BS, Kim DH, et al. Comparison betweenmatched related and alternative donors of allogeneichematopoietic stem cells transplanted into adult patients withacquired aplastic anemia: multivariate and propensity score-matched analysis [J]. Biol Blood Marrow Transplant, 2011,17(9):1289-1298.
  • 4Pillai A,Hartford C,Wang C, et, al. Favorable preliminaryresults using TLI/ATObased immunomodulatory conditioningfor matched unrelated donor allogeneic hematopoietic stem celltransplantation in pediatric severe aplastic anemia[J]. PediatrTransplant,2011,15(6): 628-634.
  • 5Lee YH, Kim JY, Choi BO, et al. Total lymphoid irradiationbased conditioning for hematopoietic stem cell transplantationin severe aplastic anemia[J]. Radiat Oncol J,2012?30(4) : 165-172.
  • 6陈惠仁,楼金星,张媛,刘晓东,杨凯,陈鹏,刘兵,何学鹏,郭智,刘丹.非血缘HLA相合供者造血干细胞移植治疗重型再生障碍性贫血的临床分析[J].中国实验血液学杂志,2012,20(4):959-964. 被引量：11
  • 7曹星玉,吴彤,卢岳,赵艳丽,周葭蕤,魏志杰,刘德琰,熊敏,张建平,陆道培.造血干细胞移植治疗重型再生障碍性贫血[J].中华器官移植杂志,2013,34(2):71-74. 被引量：6
  • 8Kanda Y,Oshima K’Kako S,et al. In vivo T-cell depletion withalemtuzumab in allogeneic hematopoietic stem celltransplantation: Combined results of two studies on aplasticanemia and HLA-mismatched haploidentical transplantation[J]. AmJ Hematol, 2013,88(4) : 294-300.
  • 9Chun C,Fang JP, Xue HM, et al. Allogeneic hematopoieticstem cell transplantation for childhood aplastic anemia:prospective trial in China [J]. Transfus Apher Sci, 2011, 44(1):41-47.
  • 10Mori T. Conditioning regimen of allogeneic hematopoietic stemcell transplantation for aplastic anemia in Japan [J]. RinshoKetsueki,2011 52(8) : 674-678.

二级参考文献93

  • 1韩伟,陆道培,黄晓军,刘开彦,陈欢,许兰平,刘代红,江倩,陈育红,路瑾,王静波,吴彤,董陆佳,任汉云.HLA配型不合造血干细胞移植GIAC方案100例临床分析[J].中华血液学杂志,2004,25(8):453-457. 被引量：68
  • 2翟卫华,王玫,周征,翟文静,张荣莉,王华,宋阿霞,冯四洲,韩明哲.异基因造血干细胞移植治疗再生障碍性贫血16例临床观察[J].中华血液学杂志,2007,28(2):78-82. 被引量：6
  • 3Russell JA, Chaudhry AM, Duggan P, et al. Daily intravenous busulfan (BU) : comparison with conventional oral BU in combination with fludarabine as conditioning for allogeneic stem cell transplant. Blood,2000,96 : 5188.
  • 4Beaman SI, Applbaum FR, Bucknr CD, et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol, 1988, 6:1562-1567.
  • 5Slavin S, Nagler A, Naparster E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood, 1998, 91:756-763.
  • 6McDonald GB, Slattely JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood, 2003, 101: 2043-2048.
  • 7Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood,2003, 102: 820-826.
  • 8Terenzi A, Aristei C, Aversa F, et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc, 1996, 28:3101.
  • 9Aversa F, Terenzi A, Tabilio F, et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase Ⅱ study in patients with acute leukemia at high risk or relapse. J Clin Oncol, 2005, 23:3447-3454.
  • 10Ji SQ, Chen HR, Yan HM, et al. Anti-CD25 monoelonal antibody (basiliximab) for prevention of graft-versns-host disease after haploidentieal bone marrow transplantation for hematological malignancies. Bone Marrow Transplant, 2005, 36: 349-354.

共引文献74

同被引文献27

引证文献3

二级引证文献6

中华器官移植杂志
2015年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部